CURRICULUM VITAE. Key Qualifications: Gastroenterology, Hepatology, Pancreatobiliary system



Similar documents
CURRICULUM VITAE. Research Interest: Gastrointestinal Pathology, Hepato-biliary pathology, Pancreas pathology

CURRICULUM VITAE. Personal Details. Surname: OZDEN First name: Mehmet Academic title/position: Assoc. Prof. Key Qualifications: Infection Immunology

CURRICULUM VITAE. Personal Details. Surname: DEMĐRDAĞ. First Name: Kutbettin. Academic title/position: Prof. Key Qualifications:

SUPERVĐSOR ĐN CHARGE OF TRAINING: Şef Dr Kunter Perim

CURRICULUM VITAE. Personal Details. Surname: Akbulut. Frst Name: Hatice Handan. Academic title/position: Prof, Departmant of Immunology

CURRICULUM VITAE. International Experience/Collaborations: Wadsworth Center, State University, Albany, New York, USA

CURRICULUM VITAE. Research Interest: Bresat Cancer, Gyneocologic Cancer, Colorectal Cancer, Lung Cancer.

CURRICULUM VITAE. Personal Details. Surname: Isik. First Name: Ahmet. Akademic title/ position: Professor of Medicine

Alanine aminotransferase (serum, plasma)

BACKGROUND MEDIA INFORMATION Fast facts about liver disease

BSc in Medical Sciences with GASTROENTEROLOGY AND HEPATOLOGY

CURRICULUM VITAE. Personal Details. Surname: Kalkan. First Name: Ahmet

NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum

2.1 AST can be measured in heparin plasma or serum. 3 Summary of clinical applications and limitations of measurements

Non-alcoholic fatty liver disease: Prognosis and Treatment

Non Alcoholic Steato-Hepatitis (NASH)

THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES. Key Points

Antioxidant response in patients with chronic hepatitis B or C.

Patterns of abnormal LFTs and their differential diagnosis

Boehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver

Service Definition with all Clinical Terms Service: Laprascopic Cholecystectomy Clinic (No Gallstones in bile duct)

Subproject 4: Specification and Documentation of Metabolic and Neoplastic Diseases

Abnormal Liver Function. Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London

Anti-HDV enzyme immunoassay index in predicting HDV viremia in serum samples

Cirrhosis and HCV. Jonathan Israel M.D.

Indications in Hepatology and Liver Diseases

CURRICULUM VITAE. Key Qualifications: Clinicaly Cardiology, Invasive Cardiology, Cardiac Electrophisology

Hepatitis B and C Co-infection. Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS

Steatosi, infiammazione e fibrosi: meccanismi patogenetici e interazioni

Albumin. Prothrombin time. Total protein

NASH: It is not JUST a Fatty Liver. Karen F. Murray, M.D. Director of Hepatobiliary Program Children s Hospital and Regional Medical Center

Comparative Levels of ALT, AST, ALP and GGT in Liver associated Diseases

The Natural History of Chronic Hepatitis B Virus Infection

Bile Duct Diseases and Problems

Hepatitis C Glossary of Terms

Acute on Chronic Liver Failure: Current Concepts. Disclosures

Viral Hepatitis Case Report

Two Cases of Non-Alcoholic Steato-Hepatitis Developing from Simple Fatty Liver

Primary Care Guidance Program: Non-Alcohol related Fatty Liver Disease (NAFLD) Guidance on Management in Primary Care

Update on Hepatitis C. Sally Williams MD

Liver Diseases. An Essential Guide for Nurses and Health Care Professionals

What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic

Transmission of HCV in the United States (CDC estimate)

LCD for Viral Hepatitis Serology Tests

Drugs Believed Capable of Inducing Autoimmune Hepatitis

Hepatitis C. Laboratory Tests and Hepatitis C

Evaluation of Liver Function tests in Primary Care. Abid Suddle Institute of Liver Studies, KCH

CURRICULUM VITAE. Personal Details. Surname: ASCI TORAMAN. First Name: ZULAL. Academic title/position: Professor

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN MEN WITH TYPE 2 DIABETES

Co-infected health-care workers

CMS Limitations Guide - Laboratory Services

Non-invasive evaluation of liver fibrosis: current clinical use and next perspectives (chronic hepatitis C)

PERINATAL AND CHILDHOOD HEPATITIS.. WHAT ABOUT THE CHILDREN?

EPIDEMIOLOGY OF HEPATITIS B IN IRELAND

Knowledge about Post-exposure Prophylaxis for Hepatitis B Virus among Dentists and Dental Students in Pakistan

Fat and Viral Liver Disease

Hepatitis Panel/Acute Hepatitis Panel

UCLA Asian Liver Program

Evaluation of a Child with Elevated Transaminases. Linda V. Muir, M.D. April 11, 2008 Northwest Pediatric Liver Disease Symposium

Liver means Life. Why this manifesto? We are eager to ensure. that we can contribute. to society as much. as possible, and we. are equally keen to

2015 Outpatient Chronic Hepatitis B Management

HBV DNA < monitoring interferon Rx

Hepatitis C. David Mutimer Queen Elizabeth Hospital Liver Unit Birmingham. Substance Misuse Treatment in the West Midlands. How can we reduce harm?

CASL Symposium Hepatitis B Co-chairs: Carla Coffin and Mang Ma

Evaluation of abnormal LFT in the asymptomatic patient. Son Do, M.D. Advanced Gastroenterology Vancouver, WA

Suna Yapali CURRICULUM VITAE. (if applicable) Marmara University,Istanbul, Turkey Residency Internal Medicine. Research Fellowship

HEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis

Medical publications on HBV and HCV Coinfection

NUTRITION IN LIVER DISEASES

Chronic Hepatitis/Chronic Active Hepatitis in Dogs

Recommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During

Hepatitis C Infections in Oregon September 2014

Prof. of Tropical Medicine Faculty of Medicine Alexandria University

Case Finding for Hepatitis B and Hepatitis C

Sovaldi (sofosbuvir) Prior Authorization Criteria

Hepatic Steatosis and Fibrosis in Chronic Hepatitis C in Taiwan

Surveillance for Hepatocellular Carcinoma

Drugs and Alcohol in Primary Care Steve Brinksman Clinical Lead SMMGP

Epidemiology of Hepatitis C Infection. Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid

WHAT S WRONG WITH MY GALL BLADDER? GALL BLADDER POLYPS

Introduction. Pathogenesis of type 2 diabetes

CURRICULUM VITAE. Key Qualifications: Internal Medicine Specialist and Medical oncologist. Name of Hospital: Firat Universitesi Hastanesi

Liver, Gallbladder, Exocrine Pancreas KNH 406

Review: How to work up your patient with Hepatitis C

HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK

Results Demographic profile of these children is shown in Table I.

Newly Diagnosed: HEPATITIS C. American Liver Foundation Support Guide

Disclosure of Conflicts of Interest Learner Assurance Statement:

Transcription:

CURRICULUM VITAE Personal Details Surname: BAHCECIOGLU First Name: Ibrahim Halil Akademic title/ position: Prof. Dr. Key Qualifications: Gastroenterology, Hepatology, Pancreatobiliary system Research Interest: Fatty liver, portal hypertension, viral hepatitis Contact Details: Work Address: Firat University, Faculty of Medicine, Division of Gastroenterology Name of Hospital: Firat University Hospital Town: Elazig Country: Turkey Post Code: 23100 Phone/Fax: 2388096 Email: ihbahcecioglu@yahoo.com Date of Birth: 14.02.1965 Place and Country of Birth: PALU/TÜRKĐYE Country of Citizenship: TÜRKĐYE Country of Training: TÜRKĐYE First Language: TÜRKÇE Languages: ĐNGĐLĐZCE Akademic Details Faculty/University ( name and address)

HACETTEPE UNIVERSITY, FACULTY OF MEDICINE-ANKARA-TURKEY Date of Graduation: 31.07.1989 Postgraduate Training: ( Name and address of Center and Supervisor [s] in charge of Training) ISTANBUL UNIVERSITY, FACULTY OF CERRAHPASA MEDICAL, DEPARTMENT OF INTERNAL MEDICINE FIRAT UNIVERSITY, FACULTY OF MEDICINE, DIVISION OF GASTROENTEROLOGY. SUPERVISOR IN CHARGE OF TRAINING: From 29.1.1990 To 27.1.1995 From 31.3.1999 to 7.06.2002 Title of thesis: Fatty liver: 100 cases Role of ocreotide on the model experimental liver fibrosis Memberships: Turkish gastroenterology association Turkish liver study association International Publications 1. Bahçecioğlu IH, Üstündağ B, Özercan Đ, Ergül E, Baydaş G, Akdere T, Demir A. Protective effect of ginkgo biloba extract on CCl4 induced liver damage. Hepatology Res 1999; 15:215-24. 2. Bahçecioğlu IH, Demir A, Üstündağ B, Đlhan M, Baydaş G, Canatan H, Özercan Đ. Protective effect of L-carnitine on alcoholic fatty liver in rats. Med Sci Res 1999; 27: 475-78. 3. Dönder E, Baydaş G, Özkan Y, Erçel E, Yalnız M, Doğan H, Bahçecioğlu IH, Investigation of antioxidant and glucometabolic effects on melatonin in experimental diabetes mellitus. Biomed Res 1999; 10: 127-32. 4. Yılmaz S, Bahçecioğlu IH. Lipid peoxidation, antioxidant enzymes and pyruvate kinase activity in rats with carbon tetrachloride-induced cirrhosis. Turk J Vet Anim Sci 2000;24:25-28. 5. Ustundag B, Canatan H, Cinkilinc N, Halifeoglu I, Bahcecioglu IH. Angiotensin converting enzyme (ACE) activity levels in insulin-independent diabetes mellitus and effect of ACE levels on diabetic patients with nephropathy. Cell Biochem Funct. 2000; 18:23-8. 6. Ozercan IH, Bahcecioglu IH, Ozercan MR, Bozlak N, Dogan C, Yekeler H. Proliferating cell nuclear antigen and nucleolar organizer region for differential diagnosis of dysplasia and adenocarcinoma in gastric biopsies. Indian J Gastroenterol.2000;19:57-60.

7. Dogukan A, Akpolat N, Celiker H, Ilhan N, Halil Bahcecioglu I, Gunal AI. Protective effect of interferon-alpha on carbon tetrachloride-induced nephrotoxicity. J Nephrol.2003;16:81-4. 8. Yalcin K, Degertekin H, Bahcecioglu IH, Demir A, Aladag M, Yildirim B, Horasanli S, Ciftci S, Badur S. Hepatitis B virus genotype D prevails in patients with persistently elevated or normal ALT levels in Turkey. Infection 2004;32:24-9. 9. Demirdag K, Bahcecioglu IH, Ozercan IH, Ozden M, Yilmaz S, Kalkan A. Role of L-carnitine in the prevention of acute liver damage induced by carbon tetrachloride in rats. J Gastroenterol Hepatol. 2004;19:333-8. 10. Celebi S, Acik Y, Deveci SE, Bahcecioglu IH, Ayar A, Demir A, Durukan P. Epidemiological features of irritable bowel syndrome in a Turkish urban society. J Gastroenterol Hepatol. 2004;19:738-43. 11.Bahcecioglu IH, Yalniz M, Ataseven H, Bulbuller N, Kececi M, Demirdag K, Ozercan I, Ustundag B. TNF-alpha and leptin in experimental liver fibrosis models induced by carbon tetrachloride and by common bile duct ligation. Cell Biochem Funct. 2004;22:359-63. 12. Bahçecioğlu IH, Yalnız M, Ataseven H, Đlhan N, Özercan ĐH. Seçkin D, Şahin K. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastroenterology. 2005;52:1549-53. 13. Bahçecioğlu IH, Yalnız M, Đlhan N. Ataseven H, Özercan IH. Levels of Serum Vitamin A, Alpha Tocopherol and Malondialdehyde in patients with non-alcoholic steatohepatitis: relationship with histopathologic severity. Int J Clin Pract 2005;59: 318-22. 14. Bolukbas FF, Bolukbas C, Zeyrek F, Aslan M, Bahcecioglu HI, Ozardali I. High rate of seropositivity of Chlamydia pneumoniae IgA in male patients with nonalcoholic steatohepatitis. Dig Dis Sci. 2005;50:1141-5. 15. Ozercan IH, Dagli AF, Ustundag B, Ozercan MR, Bahcecioglu IH, Celik H, Yalniz M, Poyrazoglu OK, Ataseven H. Does instant coffee prevent acute liver injury induced by carbon tetrachloride (CCl (4). Hepatol Res.2006;35:163-8. 16. Bahcecioglu IH, Koruk M, Yilmaz O, Bolukbas C, Bolukbas F, Tuncer I, Ataseven H, Yalcin K, Ozercan IH. Demographic and clinicopathological characteristics of nonalcoholic fatty liver disease in the East-Southeastern Anatolia regions in Turkey. Med Princ Pract. 2006;15:62-8 17. Yalniz M, Bahcecioglu IH, Ataseven H, Ustundag B, Ilhan F, Poyrazoglu OK, Erensoy A. Serum adipokine and ghrelin levels in non alcoholic steatohepatitis. Mediators Inflamm. 2006;2006(6):34295. 18. Ataseven H, Bahcecioglu IH, Kuzu N, Yalniz M, Celebi S, Erensoy A, Ustundag B. The levels of ghrelin, leptin, TNF-alpha, and IL-6 in liver cirrhosis and hepatocellular carcinoma due to HBV and HDV infection. Mediators Inflamm. 2006;2006(4):78380. 19. Kuzu N, Metin K, Dagli AF, Akdemir F, Orhan C, Yalniz M, Ozercan IH, Sahin K, Bahcecioglu IH. Protective role of genistein in acute liver damage induced by carbon tetrachloride. Mediators Inflamm.2007; 2007:36381..

20. Poyrazoglu OK, Bahcecioglu IH, Dagli AF, Ataseven H, Celebi S, Yalniz M. Heterotopic gastric mucosa (inlet patch): endoscopic prevalence, histopathological, demographical and clinical characteristics.int J Clin Pract. 2007 May 29; [Epub ahead of print] 21- Ustundag B, Bahcecioglu IH, Sahin K, Duzgun S, Koca S, Gulcu F, Ozercan IH. Protective effect of soy isoflavones and activity levels of plasma paraoxonase and arylesterase in the experimental non alcoholic steatohepatitis model. Dig Dis Sci. 2007;52:2006-14. 22. Yalniz M, Bahcecioglu IH, Kuzu N, Celebi S, Ataseven H, Ustundag B, Ozercan IH, Sahin K. Amelioration of steatohepatitis with pentoxifylline in a novel nonalcoholic steatohepatitis model induced by high-fat diet. Dig Dis Sci. 2007 ;52:2380-6. 23. Kuzu N, Bahcecioglu IH, Dagli AF, Ozercan IH, Ustündag B, Sahin K. Epigallocatechin gallate attenuates experimental non-alcoholic steatohepatitis induced by high fat diet. J Gastroenterol Hepatol. 2008 ;23(8 Pt 2):465-70. 24.Poyrazoglu OK, Ataseven H, Bektas S, Aydin A, Yalniz M, Celebi S, Bahcecioglu IH. Portal hypertension due to Echinococcus alveolaris: a case report. Acta Medica (Hradec Kralove). 2007;50:57-9. 25.Yalniz M, Bahcecioglu IH, Kuzu N, Poyrazoglu OK, Bulmus O, Celebi S, Ustundag B, Ozercan IH, Sahin K. Preventive role of genistein in an experimental non-alcoholic steatohepatitis model. J Gastroenterol Hepatol. 2007 ;22(11):2009-14. 26. Bahcecioglu IH, Ataseven H, Aygen E, Coskun S, Kuzu N, Ilhan F. Fasciola hepatica case with hemobilia. Acta Medica (Hradec Kralove). 2007;50(2):155-6. 27. Koca SS, Bahcecioglu IH, Poyrazoglu OK, Ozercan IH, Sahin K, Ustundag B. The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. Inflammation. 2008 ;31:91-8. 28. Bahcecioglu IH, Koca SS, Poyrazoglu OK, Yalniz M, Ozercan IH, Ustundag B, Sahin K, Dagli AF, Isik A. Hepatoprotective effect of infliximab, an anti-tnf-alpha agent, on carbon tetrachlorideinduced hepatic fibrosis. Inflammation. 2008 ;31:215-21. 29.Tozun N, Atug O, Imeryuz N, Hamzaoglu HO, Tiftikci A, Parlak E, Dagli U, Ulker A, Hulagu S, Akpinar H, Tuncer C, Suleymanlar I, Ovunc O, Hilmioglu F, Aslan S, Turkdogan K, Bahcecioglu HI, Yurdaydin C; Members of the Turkish IBD Study Group. Clinical Characteristics of Inflammatory Bowel Disease in Turkey: A Multicenter Epidemiologic Survey. J Clin Gastroenterol. 2008 Aug 21. 30. Bahcecioglu IH, Yalniz M, Ataseven H, Kuzu N, Ilhan F, Erensoy A. Biliary Fasciolosis: A Report of Tree Cases Diagnosed by ERCP. Acta Parasitologica Turcica (Baskıda). Presentations at International Scientific Meetings

1. Bahçecioğlu ĐH, Yalnız M, Đlhan N, Ataseven H, Özercan ĐH. Serum level of Malondialdehyde, Vitamin A, alpha Tocopherol in patients with non-alcoholic steatohepatitis. Falk Symposium, October 17-29,2003, Freiburg. 2. Yalcin K, Degertekin H, Bahcecioglu IH, Demir A. Risk factors, clinical and virological characteristics of hepatitis delta virus infection in Turkey J Hepatol 2003; 38: 631 (Suppl. 2 ). 3. Yalcin K, Bahçecioğlu ĐH, Aladağ M, Yildirim B, Değertekin H, Demir A, Badur S. Clinical profile, significance, and distribution of hepatitis B virus Genotypes among patients with chronic hepatitis B virus Infection. 12th World Congress Of The Intenational Association of Surgeons an Gastroenterologists. Hepato-Gastroenterology 2002: 49 (Suppl 2). 4. Yalniz M, Ataseven H, Bahcecioglu IH, Özercan ĐH. Is there a value of dual-energy X-ray absorptiometry in predicting the histopathologic severity of non-alcoholic steatohepatitis? J Hepatol 2003 38: 705 (Suppl. 2). 5. Ataseven H, Yildirim MH, Yalniz M, Bahçecioğlu ĐH, Ozercan IH, Celebi S and Demir A. Correlation between calibrated computerized tomographic findings and histopathologic grade/stage in non-alcoholic steatohepatitis J Hepatol 2003 38: 706 (Suppl 2). 6. Kuzu N, Bahçecioğlu ĐH, Metin K, Özercan ĐH, Tuzcu M, Yalniz M, Ustundag B, Sahin K. Role of melatonin in treatment of nonalcoholic steatohepatitis in rats induced by high fat diet. J Hepatol 2007; 46: 263.